The Synaptic Accumulation of Hyperphosphorylated Tau Oligomers in Alzheimer Disease Is Associated With Dysfunction of the Ubiquitin-Proteasome System  by Tai, Hwan-Ching et al.
The American Journal of Pathology, Vol. 181, No. 4, October 2012
Copyright © 2012 American Society for Investigative Pathology.
Published by Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.ajpath.2012.06.033Neurobiology
The Synaptic Accumulation of Hyperphosphorylated
Tau Oligomers in Alzheimer Disease Is Associated
With Dysfunction of the Ubiquitin-Proteasome SystemHwan-Ching Tai,* Alberto Serrano-Pozo,*
Tadafumi Hashimoto,* Matthew P. Frosch,†
Tara L. Spires-Jones,* and Bradley T. Hyman*
From the MassGeneral Institute of Neurodegenerative Disease *
and the C.S. Kubik Laboratory for Neuropathology,† Massachusetts
General Hospital, Harvard Medical School, Boston, Massachusetts
In Alzheimer disease (AD), deposition of neurofibril-
lary tangles and loss of synapses in the neocortex and
limbic system each correlate strongly with cognitive
impairment. Tangles are composed of misfolded hy-
perphosphorylated tau proteins; however, the link
between tau abnormalities and synaptic dysfunction
remains unclear. We examined the location of tau in
control and AD cortices using biochemical and mor-
phologic methods. We found that, in addition to its
well-described axonal localization, normal tau is pres-
ent at both presynaptic and postsynaptic terminals in
control human brains. In AD, tau becomes hyper-
phosphorylated and misfolded at both presynaptic
and postsynaptic terminals, and this abnormally
posttranslationally modified tau is enriched in synap-
toneurosomal fractions. Synaptic tau seems to be hy-
perphosphorylated and ubiquitinated, and forms sta-
ble oligomers resistant to SDS denaturation. The
accumulation of hyperphosphorylated tau oligomers
at human AD synapses is associated with increased
ubiquitinated substrates and increased proteasome
components, consistent with dysfunction of the ubiq-
uitin-proteasome system. Our findings suggest that
synaptic hyperphosphorylated tau oligomers may be
an important mediator of the proteotoxicity that dis-
rupts synapses in AD. (Am J Pathol 2012, 181:1426–1435;
http://dx.doi.org/10.1016/j.ajpath.2012.06.033)
Alzheimer disease (AD) is the most common neurode-
generative disorder in the elderly, and affects primarily
the neocortex and the limbic system, with complex
pathophysiologic features that include tau inclusions
(neurofibrillary tangles, neuropil threads, and dystrophic
1426neurites), -amyloid inclusions (plaques and cerebral amy-
loid angiopathy), loss of neurons and synapses, astroglio-
sis, microglial activation, and inflammation.1,2 Among these
features, synaptic loss3,4 and neurofibrillary tangle deposi-
tion5,6 seem to best correlate with cognitive decline.
Neurofibrillary and synaptic loss are correlated in clin-
icopathologic studies of AD7; however, whether this is a
co-occurrence of parallel pathologic processes or syn-
aptic loss is more directly related to alterations in tau
biology is uncertain.8,9 We, therefore, used new bio-
chemical and morphologic techniques to address the
issue of tau protein accumulation in synapses in the adult
human brain and in AD.
Normal tau is an abundant microtubule-associated
protein that has been described as predominantly local-
ized in axons in mature neurons.10 In AD, abnormally
folded and hyperphosphorylated tau (p-tau) accumulates
in axons, dendrites, and somas.11,12 In contrast to these
long-held generalizations, recent reports have suggested
that tau is also normally present in dendritic spines,
where it interacts with postsynaptic density (PSD) pro-
teins such as Fyn kinase.13
We hypothesized that tau may pathologically accumu-
late at synaptic sites in AD because it has been recently
suggested that tau can be present in postsynaptic lo-
cales in normal mice,13 ubiquitinated tau accumulates in
the brain in AD,14,15 and a major site of protein ubiquiti-
nation and proteasome-mediated degradation is at pre-
synaptic and postsynaptic structures.16,17 By isolating
synaptic terminals, we observed that, in control brains,
tau is present at both presynaptic and postsynaptic ter-
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brains in AD, p-tau can form stable SDS-resistant oligom-
ers that accumulate on both sides of the synapse, show-
ing synaptic enrichment when compared with the cyto-
plasm. The accumulation of p-tau at the synapse mirrors
the accumulation of ubiquitinated proteins in the same
fraction, as well as the accumulation of proteasomes and
related chaperones, which suggests that tau aggregates
are associated with impaired proteolysis mediated by the
ubiquitin-proteasome system (UPS).18
Materials and Methods
Reagents
Protease inhibitor (cOmplete tablet) was purchased from
Roche Applied Science (Roche Diagnostics Corp., Indi-
anapolis, IN). Phosphatase inhibitor cocktails 2 and 3
were purchased from Sigma-Aldrich Corp. (St. Louis,
MO) and used in a 1:1 combination. Mouse monoclonal
antibodies PHF1 (pS396/pS404 tau), CP13 (pS202 tau),
and DA9 (total tau) were gifts of Peter Davies (Albert
Einstein College of Medicine, Bronx, NY). Rabbit anti–
total tau (A20024) was purchased from Dako Denmark
A/S (Glostrup, Denmark); rabbit anti-PSD95 (No. 2507)
from Cell Signaling Technology, Inc. (Danvers, MA);
mouse anti-MBP (SMI-99P) from Covance, Inc. (Prince-
ton, NJ); mouse anti-actin (A4700), rabbit anti-actin
(A5060), and mouse anti-tubulin 3 (T8660) from Sigma-
Table 1. Characteristics of Control and AD-Affected Brains Used
Case No. Age (years) Sex
Clinical
Diagnosis
Disease
Duration (ye
C1 89 F Control NA
C2 91 F Control NA
C3 71 M Control NA
C4 87 M Control NA
C5 80 F Control NA
C6 76 M Control NA
C7 85 M Control NA
C8 57 F Control NA
C9 74 F Control NA
C10 88 F Control NA
AD1 83 F AD 13
AD2 82 M AD 6
AD3 91 F AD 14
AD4 95 M AD NA
AD5 85 F AD 4
AD6 73 F AD 19
AD7 84 F AD 16
AD8 65 M AD 8
AD9 84 F AD 7
AD10 75 F AD 5
AD11 92 F AD 9
AD12 93 M AD 17
AD13 74 M AD 11
AD14 92 M AD 22
AD15 68 F AD 11
AD16 80 F AD 12
AD17 71 F AD 17
AD18 74 M AD 17
AD19 89 M AD 10
F  female; M  male; AD  Alzheimer disease; NA  not applicabAldrich; mouse anti-synaptophysin (AB8049), mouseanti-VCP (AB19444), and rabbit anti-VDAC (AB34726)
from Abcam Inc. (Cambridge, MA); mouse anti-GAPDH
(MAB374), rabbit anti-histone H3 (05-928), and rabbit
anti-Myc (06-549) from Millipore Corp. (Billerica, MA);
and rabbit anti-ubiquitin conjugates (UG9510), mouse
anti-7 (20S subunit, PW8110), and mouse anti-Rpt1
(26S subunit, PW8852) from Enzo Clinical Laboratories,
Inc. (Farmingdale, NY).
Human Subjects
Brains from human subjects with a diagnosis of AD or no
cognitive deficits were obtained through the Massachu-
setts Alzheimer’s Disease Research Center and Massa-
chusetts General Hospital Neuropathology Department.
All donor tissue was obtained in accord with local and
national institutional review board regulations. Character-
istics of controls and subjects with AD used for quantita-
tive analyses are given in Table 1.
Subcellular Fractionation and Protein Extraction
Cortical gray matter (200 to 300 mg) taken from frozen
human brains was gently ground in a Potter-Elvehjem
homogenizer with 1.5 mL ice-cold buffer A (25 mmol/L
HEPES [pH 7.5], 120 mmol/L NaCl, 5 mmol/L KCl, 1
mmol/L MgCl2, and 2 mmol/L CaCl2) supplemented with
2 mmol/L dithiothreitol (DTT), protease inhibitors, and
phosphatase inhibitors. The homogenate was passed
ntitative Studies
ApoE
Genotype PMI (hours) Braak Stage Experiment
2/3 13 2 Figure 4
3/3 19 2 Figure 4
NA 5 0 Figure 4
NA 36 1 Figure 4
2/4 54 1 Figure 7
3/4 48 1 Figure 7
3/3 24 2 Figure 7
3/3 13 0 Figure 7
3/3 24 1 Figure 7
3/3 20 2 Figure 7
3/4 12 5 Figure 4
3/4 7 6 Figure 4
3/4 9 5 Figure 4
3/3 11 6 Figure 4
3/4 10 5 Figure 5
3/3 14 5 Figure 5
3/4 12 5 Figure 5
3/3 21 5 Figures 7, 8
3/3 7 6 Figures 7, 8
3/3 26 6 Figures 7, 8
3/3 4 6 Figures 7, 8
3/3 6 5 Figures 7, 8
3/3 15 5 Figures 7, 8
4/4 12 5 Figures 5, 7, 8
4/4 20 6 Figures 7, 8
4/4 11 6 Figures 7, 8
4/4 14 6 Figures 7, 8
4/4 20 5 Figures 7, 8
4/4 10 5 Figures 7, 8
t available; PMI  postmortem interval.in Qua
ars)through two layers of 80-m nylon filters (Millipore) to
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The saved aliquot was mixed with 200 L water and 70
L 10% SDS, passed through a 27-gauge needle, and
boiled for 5 minutes to prepare the total extract.
To prepare filtered synaptoneurosomes as described
by Hollingsworth et al,19 the remainder of the homoge-
nate was passed through a 5-m Supor membrane filter
(Pall Corp., Port Washington, NY) to remove large organ-
elles and nuclei, and centrifuged at 1000  g for 5 min-
utes. The pellet was washed once with buffer A and
centrifuged again, yielding the synaptoneurosome pellet.
Supernatant from the first centrifugation was clarified via
centrifugation at 100,000  g for 1 hour to obtain the
cytosol fraction. Cytosolic extract was prepared by add-
ing 1.5% SDS and boiling for 5 minutes. Synaptoneuro-
some pellets were extracted using 0.5 mL buffer B (50
mmol/L Tris [pH 7.5], 1.5% SDS, and 2 mmol/L DTT), and
were boiled for 5 minutes.
Sucrose Flotation Gradient
Flotation sucrose gradient for isolating synaptic terminals
was modified from previously published procedures.20
Ice-cold sucrose solutions of 0.3, 0.93, and 1.2 mol/L
were prepared using 10 mmol/L HEPES (pH 7.5). The
synaptoneurosome pellet was resuspended in 1.2
mmol/L sucrose and transferred to a centrifuge tube, and
then overlaid with 1.2, 0.93, and 0.3 mol/L sucrose to form
a three-layer discontinuous gradient. After centrifugation
at 60,000  g for 2 hours, synaptic terminals were col-
lected from the 0.93/1.2-mol/L interface, and myelin from
the 0.3/0.93-mol/L interface, and both were diluted with
water to about 0.3 mol/L final sucrose concentration. The
pellet was also resuspended in 0.3 mol/L sucrose. All
three fractions were centrifuged at 20,000  g for 20
minutes, and the pellets were extracted using buffer B
and boiled for 5 minutes.
Triton Extraction
The synaptoneurosome pellet was resuspended in ice-
cold buffer C [50 mmol/L Tris (pH 7.5), 150 mmol/L NaCl,
2% Triton X-100, and protease inhibitors]. After 20 min-
utes of incubation in a rotating tube, the mixture was
centrifuged at 100,000  g for 1 hour. The collected
Figure 1. Total SDS-soluble extracts of human AD cortices show p-tau
(detected using PHF1 and CP13) accumulation compared with controls. Actin
serves as loading control.supernatant was supplemented with 1% SDS and boiledfor 5 minutes. The pellet was extracted using buffer B and
boiled for 5 minutes.
Gel Electrophoresis and Immunoblotting
SDS-denatured protein extracts were clarified via centrifu-
gation at 20,000  g for 15 minutes, followed by bicin-
choninic acid assays (Pierce Protein Biology, Fisher Scien-
tific, Inc., Rockford, IL) to determine protein concentrations.
Extracts were boiled again for 3 minutes after adding 5X
sample buffer (250 mmol/L Tris [pH 7.5], 5% SDS, 400
mmol/L DTT, 50% glycerol, and 0.2% Orange G). Samples
were resolved via SDS-PAGE using Bis-Tris 4% to 12% gels
(Invitrogen Corp., Carlsbad, CA), and were transferred to
low-fluorescence polyvinylidene difluoride or nitrocellulose
membranes for immunoblotting, detected using an Odys-
sey laser scanner (LI-COR Biosciences, Inc., Lincoln, NE).
Blocking buffer, stripping buffer, and secondary antibodies
were purchased from LI-COR, and were used according to
the manufacturer’s protocols.
Ubiquitin Pull-Down and Tau
Immunoprecipitation
Synaptoneurosome pellets were resuspended in buffer D
(20 mmol/L Tris [pH 7.5], 150 mmol/L NaCl, 0.2% SDS,
and 4 mmol/L DTT), boiled for 5 minutes, and cleared via
centrifugation at 15,000  g for 10 minutes. The super-
natant was mixed with an equal volume of buffer E (20
mmol/L Tris [pH 7.5], 150 mmol/L NaCl, 2% Triton X-100,
Figure 2. A: Synaptoneurosomes from human cortices examined under elec-
tron microscopy show well-preserved synaptic structures (arrows). No protein
fibrils were observed in control or AD samples. B: In AD-affected brains, p-tau
oligomers (detected using PHF1 and CP13) accumulate in the synaptoneuro-
some (S) but not in the cytosol (C). Synaptophysin (Synph) and PSD95 serve as
synaptic markers. Images are representative of three independent experiments.
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mixture was pre-cleared via incubation using Protein G
Sepharose (GE Healthcare, Pittsburg, PA) at 4°C for 1
hour, followed by overnight incubation with S5a UIM aga-
rose conjugate (UW9820; Enzo Clinical Laboratories) or
protein G sepharose (control). After centrifugation at
1000  g for 2 minutes, the supernatant was collected as
the flow-through fraction. The resin was washed three
times with cold buffer F (20 mmol/L Tris [pH 7.5], 150
mmol/L NaCl, and 1% Triton X-100) and boiled for 5
minutes with 1.5X SDS-PAGE sample buffer to elute cap-
tured ubiquitinated proteins. In immunoprecipitation exper-
iments, the pre-cleared extract was incubated overnight at
4°C with rabbit anti–total tau or anti-Myc (control), followed
by incubation with protein G sepharose for 2 hours. After
centrifugation at 1000  g for 2 minutes, the supernatant
was collected as the flow-through fraction. The resin was
washed three times with cold buffer F and boiled for 5
minutes with 1.5X SDS-PAGE sample buffer to elute cap-
tured proteins. Western blots of immunoprecipitation pro-
teins were detected via enhanced chemiluminescence
using TrueBlot Ultra anti-mouse horseradish peroxidase
conjugate (eBioscience, Inc., San Diego, CA) or Clean-Blot
horseradish peroxidase conjugate (against rabbit primary
antibodies; Pierce) to minimize signals from denatured IgG.
Immunostaining of Synaptoneurosomes
Synaptoneurosome pellets were resuspended in ice-cold
buffer A, passed through 27-gauge needles, and mixed
with an equal volume of 2% paraformaldehyde in PBS-MC
(1 mmol/L MgCl2 and 1 mmol/L CaCl2) in Lab-Tek II CC2
pre-coated chamber slides (Nunc, Rochester, NY). After 10
minutes of settling at 4°C, synaptoneurosomes became
fixed and attached to the glass surface, and were washed
three times using PBS-MC (room temperature from thispoint on). Synaptoneurosomes were permeabilized using
0.05% Triton X-100 in PBS-MC with 3% bovine serum albu-
men (BSA), and washed three times. Slides were blocked
using 4% normal goat serum and 3%BSA in PBS-MC for 30
minutes and then incubated with primary antibodies diluted
in PBS-MC with 3% BSA for 2 hours, followed by three
washes. Secondary antibodies diluted in PBS-MC with 3%
BSA were incubated for 1 hour, followed by three washes.
The slide was mounted with a No. 1.5 glass coverslip and
Prolong Gold Antifade reagent (Invitrogen).
Primary antibodies for immunostaining included guinea pig
anti-vGlut1 (Millipore AB590, 1:150), chicken anti-MAP2 (Ab-
cam AB5392, 1: 100), goat anti-PSD95 (Abcam AB12093,
1:100), DA9 (1:150), and PHF1 (1:80). Fluorescent secondary
donkey antibodies were purchased from Jackson ImmunoRe-
search Laboratories, Inc. (West Grove, PA) and used at 1:100
dilutions (anti-guinea pig DyLight 649, anti-chicken Cy3, anti-
goat Alexa 488, and anti-mouse Alexa 488).
Image Acquisition and Analysis
Fluorescent and brightfield images of immunostained syn-
aptoneurosomes were acquired using an Axio Imager Z
epifluorescence microscope (Carl Zeiss AG, Oberkochen,
Germany) equipped with a 63X oil immersion objective (nu-
merical aperture, 1.40). Images were deconvolved using
the Iterative Deconvolution plug-in (by Bob Dougherty,
OptiNav, Inc.) in ImageJ software (version 1.44). Synaptic
protein co-localization was determined via manual analysis
on randomly selected areas from wide-field images.
Transmission Electron Microscopy
Synaptoneurosome pellets were fixed in 2% glutaralde-
hyde and 2% paraformaldehyde in PBS overnight at 4°C,
Figure 3. A: Human cortical synaptoneuro-
somes separated by sucrose flotation gradient to
collect highly purified synaptic terminals. B: The
purity is confirmed by immunoblotting against
organelle markers: synaptophysin (Synph; pre-
synaptic), PSD95 (postsynaptic), myelin basic
protein (MBP), mitochondrial voltage-dependent
anion channel (VDAC), histone H3, actin, and 3
tubulin. Total (T) and synaptoneurosomal (S) ex-
tracts are also loaded for comparison. C: Highly
purified synaptic terminals still contain high lev-
els of p-tau including oligomeric species. Images
are representative of three independent experi-
ments.rinsed, post-fixed in 1% osmium tetroxide, and embed-
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Hatfield, PA). Images were acquired using a transmission
electron microscope equipped with an ATM digital cam-
era (JEOL1011; JEOL USA, Inc., Peabody, MA).
Data and Statistical Analyses
Western blots were quantified via densitometry using the
gel analysis function in ImageJ software (version 1.44).
Statistical tests (paired t-test, Mann-Whitney test, two-
way analysis of variance, and linear regression) were
performed using statistical software (GraphPad version
5.03; Prism Software Corp., La Jolla, CA).
Results
p-tau Oligomers Accumulate at Synapses in AD
Proteins from control and AD cortical homogenates were
extracted using 1.5% SDS and analyzed using SDS-
PAGE. In total protein extracts, control brains exhibited
Figure 4. A: Control brain synaptoneurosomes fixed on glass slides were
immunostained against presynaptic marker vGlut1, postsynaptic marker
MAP2, and total tau (DA9 antibody). Magnifications of boxed areas rep-
resent tau immunoreactivity at individual synapses. Top, postsynaptic,
bottom, pre and postsynaptic. B: Tau proteins are also detected at
presynaptic and postsynaptic terminals from brains affected by AD. C:
Quantification of the percentage of synaptic terminals positive for tau in
control (4 cases, 400 presynapses, 276 postsynapses) and AD temporal
cortices (4 cases, 400 presynapses, 287 postsynapses). No significant
difference was found by two-way analysis of variance. Error bars repre-
sent SEM. D: Co-localization of PSD95 and MAP2 at postsynaptic sites.
Scale bars  1 m (A–D).only monomeric nonhyperphosphorylated tau (50 to 65kDa). AD-affected brains contained tau species that were
hyperphosphorylated (reactive against p-tau antibodies
CP1321 and PHF122) and migrated as a smear (Figure 1).
Fast-migrating species (15 to 50 kDa) represented trun-
cated p-tau; slow-migrating species (65 to several hun-
dred kDa) represented p-tau oligomers,23 which were
stably misfolded and resistant to SDS denaturation and
reducing agents.
To understand the subcellular localization of tau pro-
teins in AD, we separated cortical tissue homogenates
into cytosolic and synaptic (synaptoneurosome) frac-
tions. The synaptoneurosome fraction, when examined
under electron microscopy, showed well-preserved syn-
aptic structures. In both control and AD synaptoneuro-
somes, no fibrillar protein aggregates were detected
under electron microscopy (Figure 2A). Biochemical
analysis of tau in control samples showed that nonphos-
phorylated tau was more enriched in the cytosol than in
synaptoneurosomes, consistent with its expected pri-
mary distribution in the axonal cytoplasm. In contrast,
analysis of AD samples revealed that p-tau accumulated
to high levels in AD synaptoneurosomes, but remained
surprisingly absent in cytosolic extracts (Figure 2B). Con-
sidered together, our data suggest that p-tau can form
nonfibrillar aggregates associated with the synaptoneu-
rosomal pellet, containing SDS-resistant oligomers.
To examine whether the p-tau oligomers observed in
AD synaptoneurosomes were associated with syn-
apses rather than originating from other contaminants
Figure 5. A: p-Tau proteins stained using PHF1 antibody are detectable
in synaptoneurosomes in brains affected by AD but not in control brains
B: p-Tau localizes to both presynaptic (vGlut1) and postsynaptic (MAP2)
terminals. Scale bar  1 m. C: Postsynapses have higher tau-positive
percentages than do presynapses in AD temporal cortices (4 cases, 400
presynapses, 291 postsynapses). Error bars represent SEM. *P  0.05,
paired t-test.
Synaptic Tau Oligomers in AD 1431
AJP October 2012, Vol. 181, No. 4such as tau inclusions, we used sucrose gradient to
further purify synaptic terminals (Figure 3A). One po-
tential concern was that large nonfibrillar tau aggre-
gates could have co-precipitated with synaptoneuro-
somes during low-speed centrifugation (1000  g).
Because large protein assemblies are more dense
than lipid-rich vesicles, we chose a flotation gradient to
purify synaptic terminals. Flotation gradient–purified
synaptic terminals showed great reductions in organ-
elle contaminants such as nuclei and myelin (Figure
3B). In control brains, they contained low but clearly
detectable levels of nonphosphorylated monomeric
tau, suggesting a synaptic localization of tau and con-
firming recent reports of a normal role for tau at the
synapse.13,24 In AD-affected brains, they contained
high levels of p-tau including aggregate species (Fig-
ure 3C), which suggested that hyperphosphorylation
and oligomerization are specific to AD synapses.
Tau is Localized to Both Presynaptic and
Postsynaptic Terminals in Control and
AD-Affected Brains
Biochemical analysis did not demonstrate whether tau
and p-tau were localized to presynaptic or postsynaptic
terminals; therefore, we developed a new immunostain-
ing protocol to determine this. To visualize isolated syn-
aptic terminals, we spread a dilute solution of synap-
toneurosomes onto a glass slide and fixed it lightly in
place (see Materials and Methods). The fixed permeabil-
ized synaptoneurosomes were immunostained for vesic-
ular glutamate transporter 1 (vGlut1) as a presynaptic
marker, and microtubule-associated protein 2 (MAP2) as
a postsynaptic marker (Figure 4A). MAP2 is a major mi-
crotubule-binding protein in dendrites, but is also present
at lower levels inside dendritic spines and at the
PSD.25,26 We confirmed the postsynaptic localization of
Figure 6. A: Synaptoneurosomes separated into the Triton-extractable frac-
tion and the crude PSD pellet. Cytosolic protein GAPDH and membrane
proteins such as synaptophysin (Synph) and amyloid precursor protein
(APP) are mostly Triton extractable. B: The crude PSD pellet retains most of
the PSD95 protein and cytoskeleton proteins (actin and 3 tubulin). C:
Nonphosphorylated normal tau is mostly Triton extractable, but disease-
associated p-tau is retained in the crude PSD pellet. D: The pellet is also
enriched in ubiquitin conjugates (Ub Conj) and Rpt1 subunit of 26S protea-
some, but not 7 subunit of 20S proteasome. Images are representative of
three independent experiments.MAP2 by co-staining with PSD95 (Figure 4D), and notedthat PSD95 and vGlut1 often seemed to be so close as to
almost overlap, whereas MAP2 and vGlut1 seemed most
frequently to be adjacent but distinct puncta; we, therefore,
chose to use MAP2 to mark postsynaptic sites to enable
more straightforward identification of the presynaptic or
postsynaptic localization of other proteins including tau.
Using an antibody (DA9) that recognizes both phos-
phorylated and nonphosphorylated forms of tau, we de-
tected tau in many vGlut1-positive presynaptic puncta
(55.3%) and also in most MAP2-positive postsynaptic
sites (70.2%) in control human brains. In AD-affected
brains, we detected tau at 63.3% of presynaptic sites and
70.1% of postsynaptic sites (Figure 4, B and C). With
two-way analysis of variance, we did not detect a signif-
icant difference in tau distribution between presynaptic
and postsynaptic sites or between control and AD-af-
fected brains.
Under electron microscopy, approximately 80% of the
presynaptic terminals isolated from rat brains contain
visible microtubules.27 Inasmuch as tau is an abundant
microtubule-binding protein in axons, our identification of
tau in 55.3% of the presynapses is reasonable, and pos-
sibly an underestimate. With use of the same criteria,
neighboring postsynaptic structures from control brains
exhibit 70.2% tau labeling, which is consistent with recent
reports that indicated which tau may also have a post-
synaptic localization.13
p-tau is Localized to Both Presynaptic and
Postsynaptic Sites and Co-Sediments with PSD
Markers
Immunocytochemistry using PHF1 antibody did not de-
tect p-tau in control synapses, but labeled a substantial
percentage of AD synapses: 20.8% of vGlut1-positive
presynaptic puncta and 32.0% of MAP2-positive post-
synaptic puncta (Figure 5). These data support the hy-
pothesis that normal tau is already present at both pre-
Figure 7. A: In brains affected by AD, ubiquitin conjugate (Ub Conj) levels
are significantly elevated in synaptoneurosomal extracts (6 controls, 12 AD
cases, frontal cortex). GAPDH and actin are loading controls. In AD synap-
toneurosomal extracts, Rpt1 (26S proteasome subunit) and valosin-contain-
ing protein (VCP) also show significant increases. B: We also quantified
oligomeric p-tau detected using PHF1 antibody (oPHF1) in the 75- to 250-
kDa range, which is dramatically increased in AD synaptoneurosomes. Error
bars represent SEM. *P  0.05, **P  0.01, ***P  0.001, Mann-Whitney test.
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that, during the pathologic progression of AD, tau mis-
folding and hyperphosphorylation occur on both sides of
the synapse.
To understand the properties of synaptic p-tau oligom-
ers, we extracted synaptoneurosomes using 2% Triton
X-100 to solubilize membrane and free cytoplasmic pro-
teins, and the remaining insoluble material was collected as
the crude PSD pellet, which retained nearly all of the PSD95
protein and most of the actin and microtubule cytoskeleton
(Figure 6). Most of the normal tau protein in control human
synapses was extractable using Triton, and the small
amount of tau retained in the crude PSD pellet was consis-
tent withmouse studies that co-immunoprecipitated tau and
PSD95.13 In contrast, in AD synaptoneurosomes, essen-
tially all p-tau species remained in the Triton-insoluble pellet,
indicating that they were associated with the PSD and the
cytoskeleton fraction, which supports our immunostaining
data that they accumulate in dendritic spines. The crude
PSD pellet also exhibited an enrichment of ubiquitinated
proteins and ubiquitin-binding 26S proteasomes, but not
ubiquitin-nonbinding 20S proteasomes.
p-tau Accumulation, but Not A Accumulation,
is Associated with Altered Protein Turnover at
Synapses
The accumulation of p-tau oligomers at AD synapses im-
plies that the protein quality control system is overwhelmed.
The primary proteolytic mechanism for both normal and
abnormal proteins at the synapse is the UPS.28 To examine
whether there is UPS impairment at the synapse in AD, we
measured the levels of ubiquitin-protein conjugates (protea-
some substrates) in total and synaptic extracts. The synap-
tic extracts showed significant increases in ubiquitin conju-
gates in AD-affected brains compared with control brains(P 0.02; Figure 7A). This was accompanied by significant
increases in synaptic 26S proteasomes and valosin-con-
taining protein (VCP), a chaperone that delivers substrates
to proteasomes (Figure 7B). The importance of VCP in the
neuronal defense against misfolded proteins is reflected in
its known mutations that lead to frontotemporal dementia
and amyotrophic lateral sclerosis.29 The simultaneous in-
crease in proteasome substrates, proteasomes, and related
chaperones suggested reduced UPS efficiency at AD syn-
apses.
Next, we examined the correlation between p-tau
accumulation and UPS alteration in AD synaptoneuro-
somes. We found that p-tau oligomer levels positively
correlated with ubiquitin conjugate levels (P  0.007;
Figure 8A) and proteasome levels (P  0.02; Figure
8B), and to a lesser extent with VCP (P  0.08; Figure
8C). Previously, we have also quantified the synap-
toneurosomal enrichment of A monomers and oligom-
ers (2-3mer) in these AD cases using SDS-PAGE and
immunoblotting.30 We, therefore, compared the A
measures previously reported from these same cases
with the tau and UPS-related measures presented
herein. We found that within the AD group, the levels of
presumably extracellular A monomers or oligomers
did not correlate with the levels of intracellular ubiquitin
conjugates, proteasomes, or p-tau oligomers (Figure 8,
D–I). These results suggest that at AD synapses, UPS
impairment and tau abnormalities may progress to-
gether; however, the involvement of A species is
much less clear because of lack of correlation.
Synaptic p-tau at AD Synapses is Ubiquitinated
and Interacts with the 26S Proteasome
The co-enrichment of misfolded tau, ubiquitin conju-
Figure 8. Correlations of various protein measurements in
synaptoneurosomes in AD (12 cases, characterized in Figure
7). A and B: The levels of PHF1-reactive p-tau oligomers
(oPHF1, 75 to 250 kDa) positively correlate with the levels of
ubiquitin conjugates (Ub Conj, 75 to 250 kDa) and Rpt1
(subunit of 26S proteasome). C: There is a trend toward a
significant correlation between oligomeric PHF1 and valosin-
containing protein. Monomeric A (mA) (D–F) and oligo-
meric A (oA, dimers and trimers) (G–I) do not correlate
with ubiquitin conjugates, proteasomes, and oligomeric
PHF1. Linear regression is shown with 95% confidence in-
tervals (dashed lines).gates, and 26S proteasomes in the crude PSD pellet
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ubiquitinated tau at synapses may sequester protea-
somes through direct physical interaction. To verify
that synaptic tau in AD-affected brains is ubiquitinated
and capable of interacting with proteasomes, we per-
formed a ubiquitin pull-down experiment using dena-
tured synaptoneurosome extracts (Figure 9A). The
capture resin used agarose conjugated with the ubiq-
uitin-interacting motif of S5a subunit in the 26S protea-
some. Among the pool of captured proteins, which
carry ubiquitin moieties with high affinity for 26S pro-
teasomes, we detected high levels of p-tau species
including oligomers. This suggested that a tau mole-
cule can be simultaneously hyperphosphorylated and
ubiquitinated at AD synapses, in addition to being mis-
folded and aggregated. We were also able to detect
ubiquitin moieties on immunoprecipitated tau from de-
Figure 9. Synaptic p-tau oligomers in AD are ubiquitinated. A: Ubiquitinated
proteins from denatured synaptoneurosome extracts were isolated using
agarose conjugated with the ubiquitin-interacting motif (UIM) of 26S protea-
some subunit S5a. Control resin was protein G (PG)–agarose conjugates. The
captured (C) fraction and 20% of the corresponding flow-through (F) fraction
were loaded for SDS-PAGE analysis. In AD-affected brains, p-tau (PHF1-
reactive) becomes ubiquitinated and captured by UIM resin. PSD95 and actin
serve as negative controls for ubiquitin pull-down. B: Tau immunoprecipi-
tation (IP) using rabbit anti–total tau and protein G–agarose conjugates was
performed using denatured synaptoneurosomal extract. Rabbit anti-Myc was
the control antibody for IP. The captured (C) fraction and 20% of the
corresponding flow-through (F) fraction were loaded for SDS-PAGE analysis.
In AD-affected brains, synaptic tau oligomers isolated by IP are reactive
against antibodies for ubiquitin conjugates (Ub Conj) and p-tau (PHF1).
Cross-reactivity of secondary antibodies with denatured IgG heavy chain
(HC) or light chain (LC) is sometimes observed. Images are representative of
two independent experiments.natured synaptoneurosome extracts of AD-affectedbrains (Figure 9B). Immunoprecipitation also revealed
that ubiquitinated tau comprises only a small fraction of
ubiquitinated proteins at synapses, and hence the ac-
cumulation of ubiquitinated proteins in AD is sugges-
tive of general UPS dysfunction. In control brain syn-
aptoneurosomes, tau ubiquitination was below the
detection limit of our methods, which suggests that
ubiquitinated tau is efficiently degraded by UPS under
normal conditions.
Discussion
There is growing evidence that synaptic toxicity in AD
may be mediated, at least in part, by smaller, more dif-
fusible forms of misfolded A and tau aggregates, gen-
erally termed “oligomers.”9,30–32 The objective of the
present study was to examine the localization and bio-
chemical properties of synapse-associated tau oligomers.
To do so, we developed a new method to biochemically
isolate synaptoneurosomal preparations from human
brains and also to then visualize that preparation of re-
markably intact synaptic structures by smearing them on
a microscope slide. Both techniques suggested that tau
is present at both presynaptic and postsynaptic sites and
that abnormal tau dramatically accumulates at the syn-
apse in AD.
Oligomeric forms of tau including SDS-stable tau
aggregates, likely formed from noncovalent interac-
tions,23,33 are readily observed when AD-affected
brain homogenates are extracted using SDS and ana-
lyzed via SDS-PAGE under reducing conditions. Typi-
cally, tau produces a “smear” pattern in Western blots
(Figure 1). By performing subcellular fractionation be-
fore SDS extraction, we found that p-tau oligomers are
also present at high levels at AD synapses (Figures 2
and 3). Immunocytochemistry experiments further re-
vealed that p-tau accumulates in both presynaptic and
postsynaptic terminals in AD (Figure 5). Finally, we
noted that increased synaptic oligomeric tau co-occurs
with evidence of UPS dysfunction (Figures 7 and 8),
which suggests the possibility that tau accumulation is
related to an underlying defect in synaptic UPS capa-
bility, which may more generally contribute to the ac-
cumulation of pathologic proteins at the synapse.
Potential Causes of Synaptic p-tau Oligomers
Our identification of p-tau at AD synapses supports sim-
ilar observations by other groups using different meth-
ods. Applying immunohistochemistry to fixed, AD-af-
fected brains, p-tau has been observed at thorny
excrescences (large spine clusters) on CA3 hippocam-
pal dendrites.34 Using flow cytometry, another study
found p-tau in 32.3% of AD synaptosomes,35 which is in
agreement with our data.
What causes the accumulation of p-tau oligomers at
AD synapses? Two general possibilities are that tau is
normally present at both presynaptic and postsynaptic
sites, and becomes hyperphosphorylated, ubiquitinated,
and possibly misfolded in situ where it accumulates, or
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aptic sites, where it accumulates. We detected normal
tau in most presynaptic and postsynaptic terminals in
control brains (Figure 4). We also found that synaptic
p-tau aggregates are “sticky”; that is, they, remain bound
to PSD and cytoskeleton after Triton extraction (Figure 6).
To translocate to dendritic spines, misfolded p-tau with
sticky properties originating from axons or somas would
have to be transported over long distances to remote
confined spaces, which seems unlikely. Thus, we favor
the hypothesis that tau misfolding and hyperphosphory-
lation occurs in situ at both presynaptic and postsynaptic
structures.
This model would also imply impairment in the local
degradation of tau. We further explored this possibility
because the UPS has recently been shown to have a
major role in degradation of both neuronal tau36–38 and
synaptic components.28,39 We found evidence of ac-
cumulation of misfolded, posttranslationally modified
tau (hyperphosphorylated and ubiquitinated) at syn-
apses, with parallel increases in ubiquitinated proteins
and UPS components. It is likely that tau misfolding
and UPS impairment may form a vicious cycle at
synapses. Misfolded ubiquitinated tau inhibits protea-
somes,15,18 which in turn may inhibit the normal turn-
over of tau, to favor the formation of additional mis-
folded species.
Potential Toxic Effects of p-tau Oligomers
From study of postmortem brain tissues, it is difficult to
ascertain whether p-tau oligomers are toxic to synapses.
We noted, however, that numerous studies have demon-
strated that misfolded, aggregation-prone proteins are
toxic to neurons in general, including abnormal tau.8,40,41
The toxic gain-of-function of misfolded proteins is gener-
ally attributed both to the exposure of sticky, hydrophobic
surfaces on the misfolded protein and to the disruption of
protein quality control systems.42,43 Our present obser-
vations are consistent with both features: synaptic p-tau
seems to be sticky and is associated with itself and with
the PSD and cytoskeleton in a detergent-resistant fash-
ion, and p-tau oligomers also correlate well with the ac-
cumulation of proteasome substrates. We found p-tau
oligomers to be ubiquitinated and to interact directly with
the ubiquitin-interacting motif of 26S proteasomes (the
docking site of ubiquitinated substrates on protea-
somes), potentially acting as poor substrates that impede
the proteolytic enzyme.15,18 It is also conceivable that
SDS-resistant oligomers at synapses can act as seeds of
aggregation and spread tauopathy to other cellular com-
partments, or even across synapses, as implicated in
animal models of tauopathy.44,45
Synaptic tau in the Context of Other AD Lesions
The observation that misfolded tau accumulates at the syn-
apse is reminiscent of the observation that oligomeric A
also seems to accumulate at the synapse.30,46 We were
intrigued to find that A species (both monomers and oli-
gomers) did not correlate with p-tau accumulation or UPSimpairment, whereas the latter two correlated well (Figure
8). This pattern of correlation seems to correspond to the
subcellular compartmentalization of various proteins and
proteolytic systems. Intracellular nonmembrane proteins
such as tau are degraded by proteasomes37,38; therefore,
tau and UPS changes are expected to be correlated. In
contrast, extracellular A is degraded by extracellular pro-
teases such as neprilysin and insulin-degrading enzyme,
whereas intracellular A is membrane associated and may,
therefore, be degraded by lysosomal proteases.47
Our data imply that there may be an A-independent
pathologic progression at AD synapses that involves
both tau misfolding and UPS impairment. This parallels
our earlier findings that A accumulates and plateaus in
the early stage of AD and that there is a lack of correlation
between A species and late-stage disease progression
characterized by synaptic loss and NFT deposition.7
In conclusion, in the present study, we devised reliable
methods to detect tau proteins at human synapses, leading
to the demonstration that tau is a normal postsynaptic pro-
tein in addition to its traditional localization as a presynaptic
and axonal protein. In AD, we identified p-tau oligomers as
a potential synaptotoxic species that accumulates in both
presynaptic and postsynaptic terminals. The accumulation
of abnormal tau species (misfolded, hyperphosphorylated,
and ubiquitinated) parallels evidence of UPS dysfunction at
the synapse. A better understanding of the subcellular lo-
calization of abnormal tau species and their properties may
provide improved understanding of the molecular mecha-
nisms of synaptic dysfunction and loss that are believed to
underlie cognitive impairments in AD.
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